New insider activity at Hims & Hers Health ( (HIMS) ) has taken place on January 21, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CFO Oluyemi Okupe of Hims & Hers Health has executed a notable stock sale, disposing of 9,067 shares of company stock in a transaction valued at $275,092. This insider move draws attention from investors who closely watch executive trading activity as a potential signal of management’s outlook and confidence in the company’s future performance.
Recent Updates on HIMS stock
Over the past 24 hours, Hims & Hers Health has seen active trading with the stock fluctuating around the low-$30s and options volume running well above average, reflecting mixed but generally modestly bullish sentiment as call activity has led puts and implied volatility, while elevated, remains in the lower decile of its one-year range. On the fundamental side, Evercore ISI initiated coverage with a view that, while the current valuation appears reasonable, there is “multiple risk” due to expectations for a meaningful slowdown in revenue and subscriber growth and flat EBITDA margins through an investment-heavy period extending to 2026; at the same time, Evercore argues the market may be underestimating the durability and breadth of Hims’ core platform, which provides a counterpoint to near-term growth concerns. In contrast, BofA’s recent reduction in its price target is driven by the belief that consensus 2026 estimates for sales and EBITDA margins are too aggressive given that 2026 is expected to be a major investment year; BofA sees Street assumptions for margin expansion as overly optimistic and anticipates downside risk to revenue and profitability forecasts, with potential negative earnings revisions in coming months. These differing analyst views—focused on the tradeoff between continued investment, slowing growth metrics, and margin pressures versus long-term platform strength—are shaping sentiment and contributing to the choppy but highly active trading in the name.
Spark’s Take on HIMS Stock
According to Spark, TipRanks’ AI Analyst, HIMS is a Neutral.
Hims & Hers Health’s strong financial performance and positive earnings call guidance are offset by technical indicators suggesting bearish momentum and a high P/E ratio indicating overvaluation. The new share buyback program adds a positive strategic element, but high leverage remains a concern.
To see Spark’s full report on HIMS stock, click here.
More about Hims & Hers Health
YTD Price Performance: -6.16%
Average Trading Volume: 18,715,674
Technical Sentiment Signal: Hold
Current Market Cap: $7.14B